<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnostic testing for active porphyrias</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnostic testing for active porphyrias</h1>
<div class="graphic"><div class="figure"><div class="ttl">Diagnostic testing for active porphyrias</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Concurrent or recent clinical manifestations</td> <td class="subtitle1">Initial testing</td> <td class="subtitle1">Additional testing (if initial results are positive)</td> <td class="subtitle1">Types of porphyria identified</td> <td class="subtitle1">Enzyme and DNA tests</td> </tr> <tr> <td rowspan="4">Acute neurovisceral</td> <td rowspan="4">Spot urine PBG and total porphyrins (normalized with urine creatinine)</td> <td rowspan="4"> <p>Spot urine ALA, PBG, and total porphyrins (quantitative, normalized with urine creatinine)</p> <p>Plasma porphyrins*</p> <p>Erythrocyte porphyrins<sup>¶</sup></p> Fecal porphyrins</td> <td>Delta-aminolevulinic acid dehydratase porphyria (ADP)</td> <td> <p>Erythrocyte ALAD</p> Sequence <em>ALAD</em> gene</td> </tr> <tr> <td>Acute intermittent porphyria (AIP)</td> <td> <p>Erythrocyte PBGD</p> Sequence <em>PBGD</em> gene</td> </tr> <tr> <td>Hereditary coproporphyria (HCP)</td> <td>Sequence <em>CPOX</em> gene</td> </tr> <tr> <td>Variegate porphyria (VP)</td> <td>Sequence <em>PPOX </em>gene</td> </tr> <tr class="divider_top"> <td rowspan="5">Blistering photosensitivity</td> <td rowspan="5">Total porphyrins (plasma*, serum, or spot urine), with fractionation if elevated</td> <td rowspan="5"> <p>Erythrocyte total porphyrins</p> <p>Urinary ALA and PBG</p> <p>Fecal total porphyrins</p> </td> <td>Porphyria cutanea tarda (PCT)</td> <td> <p>Erythrocyte UROD</p> Sequence <em>UROD</em> gene<sup>Δ</sup></td> </tr> <tr> <td>Hepatoerythropoietic porphyria (HEP)</td> <td> <p>Erythrocyte UROD</p> Sequence <em>UROD</em> gene</td> </tr> <tr> <td>HCP</td> <td>Sequence <em>CPOX</em> gene</td> </tr> <tr> <td>VP</td> <td>Sequence <em>PPOX </em>gene</td> </tr> <tr> <td>Congenital erythropoietic porphyria (CEP)</td> <td> <p>Erythrocyte UROS</p> Sequence <em>UROS</em> gene</td> </tr> <tr class="divider_top"> <td rowspan="2">Nonblistering photosensitivity</td> <td rowspan="2">Total erythrocyte porphyrins<sup>¶</sup></td> <td rowspan="2">Erythrocyte metal-free and zinc protoporphyrin; plasma total porphyrins and fluorescence scan</td> <td>Erythropoietic protoporphyria (EPP)</td> <td>Sequence <em>FECH</em> gene</td> </tr> <tr> <td>X-linked protoporphyria (XLP)</td> <td>Sequence <em>ALAS2</em> gene</td> </tr> </tbody></table></div><div class="graphic_lgnd">First-line testing for symptomatic patients is guided by clinical features (ie, neurovisceral, cutaneous chronic blistering, or cutaneous acute nonblistering). All spot urine measurements should be normalized with spot urine creatinine. If initial testing is positive, further comprehensive testing follows to identify the type of acute porphyria. Enzyme measurements may be used but are not available for all porphyrias. DNA testing usually follows establishment of a biochemical diagnosis. Refer to UpToDate topics on overview of porphyria and specific porphyrias for additional details and testing in asymptomatic patients.</div><div class="graphic_footnotes">PBG: porphobilinogen; ALA: delta-aminolevulinic acid; ADP: delta-aminolevulinic acid dehydratase porphyria; ALAD: delta-aminolevulinic acid dehydratase; PBGD: porphobilinogen deaminase; CPOX: coproporphyrinogen oxidase; PPOX: protoporphyrin oxidase; UROD: uroporphyrinogen decarboxylase; UROS: uroporphyrinogen III synthase; FECH: ferrochelatase; ALAS2: delta-aminolevulinate synthase-2.<br/>* Plasma porphyrins should include measurement of the total, fractionation if the total is elevated, and determination of the fluorescence peak wavelength at neutral pH.<br/>¶ It is important to verify that the method used by the laboratory measures all erythrocyte porphyrins and not just zinc protoporphyrin.<br/>Δ<sup> </sup>UROD mutations are neither required nor specific for a diagnosis of PCT. UROD mutations are found in approximately 20% of patients with PCT and therefore are helpful if present. The presence of a UROD mutation is a predisposing factor but not sufficient to cause PCT.</div><div id="graphicVersion">Graphic 89036 Version 12.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
